FDA Review Extension for Ascendis Pharma's TransCon CNP
Ascendis Pharma A/S (NASDAQ: ASND), a prominent player in biopharmaceutical innovations, has received noteworthy news regarding its investigational therapy, TransCon CNP (navepegritide). The U.S. Food and Drug Administration (FDA) has effectively extended the Prescription Drug User Fee Act (PDUFA) target action date by three months, pushing the deadline to February 28, 2026.
Implications of the Extension
This extension signifies the FDA's acknowledgment of a major amendment to the New Drug Application (NDA) submitted by Ascendis Pharma. The amendment, which was part of the company’s response on November 5, 2025, addressed a post-marketing requirement tied to the ongoing NDA review for TransCon CNP, aimed at children diagnosed with achondroplasia.
CEO's Statement on Collaboration with the FDA
Jan Mikkelsen, the President and CEO of Ascendis Pharma, expressed confidence in their collaborative efforts with the FDA. He stated, "We have responded to all outstanding requests from the FDA, including the request for a revised protocol for the post-marketing study, which we received as the lone item for discussion at our late-cycle meeting." His commitment to refining the post-marketing requirement demonstrates Ascendis’ dedication to successfully delivering this innovative therapy to patients in the United States.
About Ascendis Pharma
Founded in Copenhagen, Denmark, Ascendis Pharma has rapidly established itself as a global biopharmaceutical company. Its innovative TransCon technology platform is pivotal in developing new therapies aimed at unmet medical needs, especially for patients requiring specialized treatments. Ascendis operates through core values centered around Patients, Science, and Passion, striving for excellence in all its endeavors.
The TransCon Technology
TransCon technology stands as a cornerstone of Ascendis' product development strategy. This platform is designed to address significant challenges faced in the therapeutic space, particularly for patients dealing with chronic conditions. By focusing on long-acting medicines, Ascendis aims to enhance patient compliance and treatment outcomes.
Looking Ahead: What’s Next for Ascendis Pharma?
With the new PDUFA goal date set, Ascendis Pharma is actively engaged in finalizing all necessary elements to streamline the approval process for TransCon CNP. The company is leveraging its expertise and innovative capabilities to bring this much-anticipated therapy to the market, pending FDA approval.
Investor and Media Contact Information
For those interested in learning more about Ascendis Pharma and its commitment to innovation, the following contacts are available:
Investor Contact: Chad Fugere
Email: ir@ascendispharma.com
Media Contact: Melinda Baker
Email: media@ascendispharma.com
Frequently Asked Questions
What is TransCon CNP?
TransCon CNP (navepegritide) is a therapy developed by Ascendis Pharma aimed at treating children with achondroplasia, a common form of dwarfism.
Why was the FDA review period extended?
The FDA extended the review period to evaluate a major amendment related to post-marketing requirements that Ascendis submitted as part of their NDA.
What are the key commitments from Ascendis Pharma?
Ascendis Pharma is committed to closely working with the FDA to finalize all aspects of the post-marketing study to ensure patient access to TransCon CNP.
How does TransCon technology impact patient care?
The TransCon technology is designed to offer long-acting medications that can improve patient adherence and treatment effectiveness over time.
Where is Ascendis Pharma headquartered?
Ascendis Pharma is headquartered in Copenhagen, Denmark, with a global presence that includes additional facilities in Europe and the United States.
